This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spengler, M. L. Articles by Azizkhan-Clifford, J. Search for Related Content PubMed PubMed Citation Articles by Spengler, M. L. Articles by Azizkhan-Clifford, J.

 Previous Article  |  Next Article 

Journal of Virology, March 2002, p. 2990-2996, Vol. 76, No. 6
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.6.2990-2996.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

SUMO-1 Modification of Human Cytomegalovirus IE1/IE72

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York,¹ Department of Biochemistry, MCP Hahnemann University, Philadelphia, Pennsylvania²

Received 18 May 2001/ Accepted 17 December 2001

Human cytomegalovirus (HCMV) immediate-early protein IE1/IE72 is involved in undermining many cellular processes including cell cycle regulation, apoptosis, nuclear architecture, and gene expression. The multifunctional nature of IE72 suggests that posttranslational modifications may modulate its activities. IE72 is a phosphoprotein and has intrinsic kinase activity (S. Pajovic, E. L. Wong, A. R. Black, and J. C. Azizkhan, Mol. Cell. Biol. 17:6459-6464, 1997). We now demonstrate that IE72 is covalently conjugated to the small ubiquitin-like modifier (SUMO-1). SUMO-1 is an 11.5-kDa protein that is conjugated to multiple proteins and has been reported to exhibit multiple effects, including modulation of protein stability, subcellular localization, and gene expression. A covalently modified protein migrating at 92 kDa, which is stabilized by a SUMO-1 hydrolase inhibitor, is revealed by Western blotting with anti-IE72 of lysates from cells infected with HCMV or cells expressing IE72. SUMO modification of IE72 was confirmed by immunoprecipitation with anti-IE72 and anti-SUMO-1 followed by Western blotting with anti-SUMO-1 and anti-IE72, respectively. Lysine 450 is within a sumoylation consensus site (I,V,L)KXE; changing lysine 450 to arginine by point mutation abolishes SUMO-1 modification of IE72. Inhibition of protein phosphatase 1 and 2A, which increases the phosphorylation of IE72, suppresses the formation of SUMO-1-IE72 conjugates. Both wild-type IE72 and IE72_K450R localize to nuclear PML oncogenic domains and disrupt them. Studies of protein stability, transactivation, and complementation of IE72-deficient HCMV (CR208) have revealed no significant differences between wild-type IE72 and IE72_K450R.

This article has been cited by other articles:

• Kang, H., Kim, E. T., Lee, H.-R., Park, J.-J., Go, Y. Y., Choi, C. Y., Ahn, J.-H. (2006). Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein.. J. Gen. Virol. 87: 2181-2190 [Abstract] [Full Text]  
• Spengler, M. L., Brattain, M. G. (2006). Sumoylation Inhibits Cleavage of Sp1 N-terminal Negative Regulatory Domain and Inhibits Sp1-dependent Transcription. J. Biol. Chem. 281: 5567-5574 [Abstract] [Full Text]  
• Reinhardt, J., Smith, G. B., Himmelheber, C. T., Azizkhan-Clifford, J., Mocarski, E. S. (2005). The Carboxyl-Terminal Region of Human Cytomegalovirus IE1491aa Contains an Acidic Domain That Plays a Regulatory Role and a Chromatin-Tethering Domain That Is Dispensable during Viral Replication. J. Virol. 79: 225-233 [Abstract] [Full Text]  
• Chang, L.-K., Lee, Y.-H., Cheng, T.-S., Hong, Y.-R., Lu, P.-J., Wang, J. J., Wang, W.-H., Kuo, C.-W., Li, S. S.-L., Liu, S.-T. (2004). Post-translational Modification of Rta of Epstein-Barr Virus by SUMO-1. J. Biol. Chem. 279: 38803-38812 [Abstract] [Full Text]  
• Nevels, M., Brune, W., Shenk, T. (2004). SUMOylation of the Human Cytomegalovirus 72-Kilodalton IE1 Protein Facilitates Expression of the 86-Kilodalton IE2 Protein and Promotes Viral Replication. J. Virol. 78: 7803-7812 [Abstract] [Full Text]  
• Lee, H.-R., Kim, D.-J., Lee, J.-M., Choi, C. Y., Ahn, B.-Y., Hayward, G. S., Ahn, J.-H. (2004). Ability of the Human Cytomegalovirus IE1 Protein To Modulate Sumoylation of PML Correlates with Its Functional Activities in Transcriptional Regulation and Infectivity in Cultured Fibroblast Cells. J. Virol. 78: 6527-6542 [Abstract] [Full Text]  
• Gravel, A., Dion, V., Cloutier, N., Gosselin, J., Flamand, L. (2004). Characterization of human herpesvirus 6 variant B immediate-early 1 protein modifications by small ubiquitin-related modifiers. J. Gen. Virol. 85: 1319-1328 [Abstract] [Full Text]  
• Wood, L. D., Irvin, B. J., Nucifora, G., Luce, K. S., Hiebert, S. W. (2003). Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc. Natl. Acad. Sci. USA 100: 3257-3262 [Abstract] [Full Text]  
• Ma, H. J., Sjak-Shie, N. N., Vescio, R. A., Kaminsky, M., Mikail, A., Pold, M., Parker, K., Beksac, M., Belson, D., Moss, T. J., Wu, C. H., Zhou, J., Zhang, L., Chen, G., Said, J. W., Berenson, J. R. (2000). Human Herpesvirus 8 Open Reading Frame 26 and Open Reading Frame 65 Sequences from Multiple Myeloma Patients: A Shared Pattern Not Found in Kaposi's Sarcoma or Primary Effusion Lymphoma. Clin. Cancer Res. 6: 4226-4233 [Abstract] [Full Text]